BRPI1009663A2 - "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica" - Google Patents

"método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"

Info

Publication number
BRPI1009663A2
BRPI1009663A2 BRPI1009663A BRPI1009663A BRPI1009663A2 BR PI1009663 A2 BRPI1009663 A2 BR PI1009663A2 BR PI1009663 A BRPI1009663 A BR PI1009663A BR PI1009663 A BRPI1009663 A BR PI1009663A BR PI1009663 A2 BRPI1009663 A2 BR PI1009663A2
Authority
BR
Brazil
Prior art keywords
individual
requirement
need
pharmaceutical composition
platelet levels
Prior art date
Application number
BRPI1009663A
Other languages
English (en)
Portuguese (pt)
Inventor
Amnon Peled
Michal Abraham
Orly Eizenberg
Original Assignee
Biokine Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokine Therapeutics Ltd filed Critical Biokine Therapeutics Ltd
Publication of BRPI1009663A2 publication Critical patent/BRPI1009663A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI1009663A 2009-06-14 2010-06-13 "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica" BRPI1009663A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18685709P 2009-06-14 2009-06-14
PCT/IL2010/000466 WO2010146578A2 (en) 2009-06-14 2010-06-13 Peptide therapy for increasing platelet levels

Publications (1)

Publication Number Publication Date
BRPI1009663A2 true BRPI1009663A2 (pt) 2016-10-11

Family

ID=43356827

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009663A BRPI1009663A2 (pt) 2009-06-14 2010-06-13 "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"

Country Status (11)

Country Link
US (1) US9427456B2 (OSRAM)
EP (1) EP2442822B1 (OSRAM)
JP (1) JP5715622B2 (OSRAM)
KR (1) KR101719339B1 (OSRAM)
CN (1) CN102481332A (OSRAM)
BR (1) BRPI1009663A2 (OSRAM)
CA (1) CA2765345C (OSRAM)
ES (1) ES2462517T3 (OSRAM)
IL (1) IL216912A (OSRAM)
MX (1) MX2011013459A (OSRAM)
WO (1) WO2010146578A2 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
WO2008075370A2 (en) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2012095849A1 (en) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
JP2015154715A (ja) * 2012-05-22 2015-08-27 国立大学法人旭川医科大学 ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
WO2014089478A1 (en) * 2012-12-07 2014-06-12 University Of Tennessee Research Foundation Methods of numerical analysis for platelet disorders and computer-readable media and systems for performing the same
AU2015258840B2 (en) 2014-05-15 2018-03-15 Enzychem Lifesciences Corporation Methods for treating leukopenia and thrombocytopenia
JP6547274B2 (ja) 2014-10-20 2019-07-24 株式会社デンソー 粒子状物質検出センサ
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10993985B2 (en) 2016-02-23 2021-05-04 BioLmeRx Ltd. Methods of treating acute myeloid leukemia
JP2022523295A (ja) * 2019-01-25 2022-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 発疱剤および苛性ガスの毒性作用を緩和する方法
WO2021181398A1 (en) * 2020-03-11 2021-09-16 Biolinerx Ltd. Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
AU2021412499A1 (en) 2020-12-30 2023-08-10 Biokine Therapeutics Ltd. Composition of bl-8040
MX2023007868A (es) 2020-12-30 2023-07-10 Biolinerx Ltd Procedimiento de fabricacion de peptido.
CN118027155B (zh) * 2024-04-15 2024-07-16 中国人民解放军军事科学院军事医学研究院 一种tpor结合肽及其应用
WO2025259130A1 (ru) * 2024-06-11 2025-12-18 Consumer Cooperative "Vse" ПРИМЕНЕНИЕ ПЕПТИДА Ac-His-Ala-Glu-Glu-NH2 ДЛЯ ВОССТАНОВЛЕНИЯ ДЕФИЦИТА ЭНДОГЕННОГО КОМПОНЕНТА КРОВИ ЖИВОТНЫХ
WO2025259133A1 (ru) * 2024-06-11 2025-12-18 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации Пептид ac-his-ala-glu-glu-nh2 и его производные, предназначенные для восстановления дефицита эндогенного компонента крови человека

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
EP1018552B1 (en) 1985-08-23 2006-07-05 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3681551D1 (de) 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH0618778B2 (ja) 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
CA1297005C (en) 1986-01-22 1992-03-10 Masahiko Tamura Pharmaceutical agent for the treatment of myelogenous leukemia
ATE65403T1 (de) 1986-01-22 1991-08-15 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
ATE111921T1 (de) 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
CA1339071C (en) 1988-08-24 1997-07-29 Koichiro Tsuji Thrombus control agent
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
EP0459516A1 (en) 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
CZ287239B6 (en) 1993-10-14 2000-10-11 Seikagaku Kogyo Co Ltd Polypeptides exhibiting antimicrobial and antiviral activity and pharmaceutical preparations containing thereof
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5492126A (en) 1994-05-02 1996-02-20 Focal Surgery Probe for medical imaging and therapy using ultrasound
JP4562815B2 (ja) 1997-05-21 2010-10-13 ジェネンテック， インコーポレイテッド トロンボポエチンの新規な投与
ATE419789T1 (de) 1997-05-23 2009-01-15 Prorhythm Inc Wegwerfbarer fokussierender ultraschallapplikator hoher intensität
US6569418B1 (en) 1997-12-11 2003-05-27 University Of Maryland Biotechnology Institute Immuno-modulating effects of chemokines in DNA vaccination
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US6946445B1 (en) 1998-03-13 2005-09-20 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
AU5241099A (en) 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
CA2345817C (en) 1998-10-05 2013-02-12 M&E Biotech A/S Novel methods for therapeutic vaccination
EP1124614A1 (de) 1998-10-27 2001-08-22 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Verfahren und vorrichtung zur regelung einer gezielten wärmedeponierung in ein material
US20060079492A1 (en) 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
EP1165096B1 (en) 1999-03-29 2009-09-09 Shire Canada Inc. Use of cytidine derivatives for the treatment of leukaemia
EP1232185A2 (en) 1999-11-24 2002-08-21 Schering Corporation Methods of inhibiting metastasis
WO2001064716A1 (fr) 2000-03-03 2001-09-07 Nobutaka Fujii Composes antiviraux
DE60103052T2 (de) * 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
AU2001284419A1 (en) * 2000-09-05 2002-03-22 Seikagaku Corporation Novel polypeptides and anti-hiv drugs containing the same
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7630750B2 (en) 2001-02-05 2009-12-08 The Research Foundation For The State University Of New York Computer aided treatment planning
JP3374917B2 (ja) 2001-02-16 2003-02-10 サンケン電気株式会社 スイッチング電源装置
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
WO2004052862A1 (ja) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
JP2006524242A (ja) 2003-03-27 2006-10-26 エモリー ユニバーシティー Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US8012136B2 (en) 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
US7419667B2 (en) 2004-03-19 2008-09-02 Morinaga Milk Industry Co. Ltd. Drug for cancer therapy
EP1796716A4 (en) * 2004-08-13 2010-09-08 Anormed Inc COMBINATIONS OF CHEMOKINES FOR MOBILIZING PROGENITOR / STEM CELLS
US20080233053A1 (en) 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
CA2619828A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
WO2007067280A2 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Very small embryonic-like (vsel) stem cells and methods of isolating and using the same
US20080038231A1 (en) 2006-06-15 2008-02-14 Rodgerson Denis O Processing procedure for peripheral blood stem cells
AU2007281090A1 (en) 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
WO2008016141A1 (fr) 2006-08-04 2008-02-07 Kurume University Peptide dérivé de kif capable de se lier à une molécule hla-a24
WO2008075370A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
MX2011013457A (es) 2009-06-15 2012-05-08 Biokine Therapeutics Ltd Polipeptidos que enlazan quimioquina novedosos capaces de inhibir el curso de autoinmunidad, inflamacion y cancer.
US20120082687A1 (en) 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
WO2012095849A1 (en) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
MX363896B (es) 2013-03-24 2019-04-05 Biokine Therapeutics Ltd Combinación de un antagonista de cxcr4y y citarabina para el uso en el tratamiento de leucemia mieloide.
EP3030322A2 (en) 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
US20160243187A1 (en) 2013-10-31 2016-08-25 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation

Also Published As

Publication number Publication date
CN102481332A (zh) 2012-05-30
JP2012530130A (ja) 2012-11-29
CA2765345C (en) 2016-06-21
WO2010146578A2 (en) 2010-12-23
WO2010146578A3 (en) 2011-02-10
IL216912A0 (en) 2012-02-29
US20120094907A1 (en) 2012-04-19
US9427456B2 (en) 2016-08-30
MX2011013459A (es) 2012-05-08
JP5715622B2 (ja) 2015-05-07
EP2442822B1 (en) 2014-03-05
EP2442822A4 (en) 2013-01-23
ES2462517T3 (es) 2014-05-23
CA2765345A1 (en) 2010-12-23
KR20120037463A (ko) 2012-04-19
KR101719339B1 (ko) 2017-03-23
EP2442822A2 (en) 2012-04-25
IL216912A (en) 2015-09-24

Similar Documents

Publication Publication Date Title
BRPI0908637A2 (pt) composto; composição farmacêutica do mesmo e método para inibição de proliferação celular em um indivíduo.
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BR112012015540A2 (pt) composto, uso de composto, método para tratar um individuo, método de inibir janus quinases em um individuo, composição farmacêutica e combinação de produto
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0905912A2 (pt) "métodos para a detecção de um microorganismo alvo e composição para detecção de microorganismo alvo"
BRPI0914406A2 (pt) composto, composição farmacêutica, e, método para aumentar os níveis no plasma de apo a1 em um mamífero
EP2345410A4 (en) PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0909183A2 (pt) Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
BRPI0910406A2 (pt) equipamento e métodos para otmimização de tranporte para entrega de conteúdo widget
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI1013002A2 (pt) sistemas e métodos para entrega de conteúdo
BR112013015010A2 (pt) produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana
BRPI0911681A2 (pt) composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula
BRPI0821876A8 (pt) sistemas e métodos para administração de medicação
BRPI0807918A2 (pt) composições e método para preservação de tecido
CL2007002787A1 (es) Compuestos derivados de n-cicloalquil-carboxamida, n-cicloalquil-tiocarboxamida y n-cicloalquil-carboxamidamida n-sustituida; composicion fungicida que comprende dichos compuestos; y metodo para combatir hongos fitopatogenos de cultivos que comprende
BRPI1014824A2 (pt) composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
PT2769729T (pt) Polipéptidos e polinucleótidos, e utilizações dos mesmos como um alvo de fármacos para produzir fármacos e agentes biológicos

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL